NT5E and COVID-19: Dorneles et al. showed a higher percentage of CD4+CD39+ cells in severe COVID-19 patients than in healthy controls and a lower percentage of CD4+CD73+ cells than in controls [30], suggesting that this could be a useful marker to follow progression in the general population with COVID-19.